Fred Valentine, MD, Infectious Disease, New York, NY, NYC Health + Hospitals / Bellevue

FredTownsendValentineMD

Infectious Disease New York, NY

Professor, Medicine, New York University School of Medicine

Dr. Valentine is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Valentine's full profile

Already have an account?

Education & Training

  • Harvard Boston City HospResidency, 1960 - 1965
  • Harvard Medical SchoolClass of 1960

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1965 - 2019
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • AdministrativeNational Institute Of Allergy And Infectious Diseases2010
  • Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2000–2010
  • Immunopathogenesis Of Acute And Early HIV InfectionNational Institute Of Allergy And Infectious Diseases2004–2009
  • CD4 Responses To Antiretroviral Therapy (ART) Alone Or ART With VaccinationNational Center For Research Resources2006–2008
  • Immunological Control Of HIV In VivoNational Institute Of Allergy And Infectious Diseases2004–2008
  • Immune Responses To Acute HIV InfectionNational Institute Of Allergy And Infectious Diseases2004–2008
  • OAR SupplementNational Institute Of Allergy And Infectious Diseases2005
  • Administrative CoreNational Institute Of Allergy And Infectious Diseases2005
  • ACTG A5150: Virologic &Immunologic Changes In Women With HIV During PostpartumNational Center For Research Resources2005
  • ACTG A5116: Protease Inhibitor Sparing Regimens V Nucleoside-Sparing RegimensNational Center For Research Resources2005
  • ACTG A5082: Metformin &Rosiglitazone In HIV+ PTS W/ Insulin &Fat AbnormalitiesNational Center For Research Resources2004–2005
  • ACTG 5084: Metabolic Complications In Hiv-1-Infected Pregnant Women On ARTNational Center For Research Resources2004–2005
  • HIV Pathogenesis And Responoses To Therapy In AfricansNational Institute Of Allergy And Infectious Diseases2004
  • Temporary Cessation Of Antiretroviral Treatment In Patients Failing TherapyNational Center For Research Resources2004
  • Predictive Value Of Pk-Adjusted Phenotypic Susceptibility On Antiretroviral RESPNational Center For Research Resources2004
  • Effect Of Thymidine Analogue Change To Nucleoside-Sparing Regimen On Fat WastingNational Center For Research Resources2004
  • Augmentation Of Immune Response Through Vaccination In Individuals On HaartNational Center For Research Resources2004
  • Adult AIDS Clinical Trial Group Longitudinal Linked Randomized Trials ProtocolNational Center For Research Resources2004
  • ACTG A5173:Clearance Of HIV-1 In CD4+ Cells Of Subjects On T-20 PLUS Oral ARNational Center For Research Resources2004
  • ACTG A5172: Using Helper And CTL Responses To Control VNational Center For Research Resources2004
  • ACTG A5164:Immediate VS Delayed ART For Hiv-Infected Patients With Acute OTNational Center For Research Resources2004
  • ACTG A5163: Alendronate In HIV Subjects With DecreasedNational Center For Research Resources2004
  • ACTG A5150: Virologic &Immunologic Changes In Women WINational Center For Research Resources2004
  • ACTG A5146: Therapeutic Drug Monitoring In Subjects With A Low Niq To PisNational Center For Research Resources2004
  • ACTG A5143: Lopinavir (Lpv)/Ritonavir (RTV) VS Gw433908/Rtv VS Lpv/Rtv/Gw433908National Center For Research Resources2004
  • ACTG A5135: Fixed- VS Adjusted-Dose Lopinavir/RitonavirNational Center For Research Resources2004
  • ACTG A5128: Obtaining Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2004
  • ACTG A5127: Treatment Of Lamivudine-Resistant HBV/HIV Co-Infected SubjectsNational Center For Research Resources2004
  • ACTG A5116: Protease Inhibitor Sparing Regimens V. Nucleoside-Sparing RegimensNational Center For Research Resources2004
  • ACTG A5115: Antiretroviral Switch At Lower Versus Higher HIV-1 RNA LevelsNational Center For Research Resources2004
  • ACTG A5103:Protease Inhibitor-Sparing Regimens To Improve Metabolic AbnormalitieNational Center For Research Resources2004
  • ACTG A5095: 3 Protease Inhibitor-Sparing Regimens For Initial Treatment Of HIVNational Center For Research Resources2004
  • ACTG A5092s: Pharmacokinetic Effects Of Rbv On ZDV Or D4T Triphosphate FormationNational Center For Research Resources2004
  • ACTG A5079: Testosterone Supplementation For Hiv-Positive MenNational Center For Research Resources2004
  • ACTG A5073:Twice Daily -V- Once Daily Haartand Self-Administered Versus DOTNational Center For Research Resources2004
  • ACTG A5068: Withdrawal Of Antiretrovirals + HIV VaccineNational Center For Research Resources2004
  • ACTG A5030: Valganciclovir For Pre-Emptive Therapy For CytomegalovirusNational Center For Research Resources2004
  • ACTG A5029: Human Papilloma Virus In Antiretroviral Naive HIV+ Women On HaartNational Center For Research Resources2004
  • ACTG 736: CSF HIV-1 &Cognitive Function In Patients On Potent HaartNational Center For Research Resources2004
  • ACTG 372: Indinavir + Nucleoside Analogs: Virologic Success And FailureNational Center For Research Resources2004
  • ACTG 371: 3tc/Zdv/Abc/Apv In Acute HIV Infection Or SeroconversionNational Center For Research Resources2004
  • ACTG A5170: Predictors Of Disease Progression In Subjects WHO Discontinue ARTNational Center For Research Resources2004
  • ACTG A5142: Comparison Of Three Antiviral Regimens For Initial Therapy Of HIV-1National Center For Research Resources2004
  • ACTG 362: Azithromycin Prophylaxis For Primary Prevention Of MAC In AIDSNational Center For Research Resources1999–2004
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–2003
  • TRI 003: T 20 Administered To HIV+ Adults By SQ Infusion V SQ InjectionNational Center For Research Resources1999–2002
  • ACTG 398: Amprenavir + Abacavir, Efavirenz &Adefovir In HIV+ PTSNational Center For Research Resources1999–2002
  • ACTG 388: Efz + Nfv W/ 3tc/Zdv &Idv In HIV+ PTS W/ CD4 <200 &>100,National Center For Research Resources1999–2002
  • ACTG 384: PI +/ Nnrti W/ Dual Nucleosides For Initial RX Of HIV InfectionNational Center For Research Resources1999–2002
  • ACTG 365:Steady State Pharmacokinetic Interaction Study Of IndinavirNational Center For Research Resources1999–2002
  • ACTG 363: Cidofovir For Progressive Multifocal Leukoencephalopathy In AIDSNational Center For Research Resources1999–2002
  • ACTG 334:Cyclosporin In Immune Activation &Hiv Expression In Early HIVNational Center For Research Resources1999–2002
  • Zdv/3tc/Nevirapine And Zdv/3tc/Nevirapine/1592u89 In Hiv-Infected ChildrenNational Center For Research Resources1998–2002
  • Three Regimens For Hiv-Infected Subjects On Zdv, Lamivuidine And IndinavirNational Center For Research Resources1998–2002
  • Rhil2 In HIV+ Subjects On Haart Compared To Haart AloneNational Center For Research Resources1998–2002
  • Oral Isotretinoin Versus Observation For Low Grade Cervical DysplasiaNational Center For Research Resources1998–2002
  • Nelfinavir AND/OR Dmp-266 PLUS Nucleoside Analogs In Nucleoside ExperienceNational Center For Research Resources1998–2002
  • Indinavir, Dmp-266 And 1592U89 In Hiv-Infected SubjectsNational Center For Research Resources1998–2002
  • Indinavir PLUS Nucleoside Analogs--Virologic Success And FailureNational Center For Research Resources1998–2002
  • Fluconazole In HIV+ Subjects With Recurrent Oropharyngea CandidiasisNational Center For Research Resources1998–2002
  • Activity Of Soft Gel Capsule Of Saquinavir In Antiretroviral RegimensNational Center For Research Resources1998–2002
  • 141w94/Vx-478+3tc+Zdv Or Nevirapine+3tc+StavudineNational Center For Research Resources1998–2002
  • 141w94/Vx-478 PLUS ZDV PLUS 3TC In Hiv-Infected IndividualsNational Center For Research Resources1998–2002
  • ACTG 320--Indinavir W/ ZDV Or D4T &3tc In PTS W/ Cd4<200 &>3 Mon Prior ZDVNational Center For Research Resources1997–2002
  • ACTG 307--Hydroxyurea +/- DDI Compared With DDI Alone In HIV Infected PatientsNational Center For Research Resources1997–2002
  • Lymphokines On Metastatic Malignant MelanomaNational Center For Research Resources1996–2002
  • IL-2 PLUS Antiretroviral Therapy Versus Antiretroviral Alone In HIV+ PatientsNational Center For Research Resources1996–2002
  • Core--Flow Cytometry FacilityNational Institute Of Allergy And Infectious Diseases2001
  • Cryptic Epitopes--Immunization By Multiple Chain PeptideNational Institute Of Allergy And Infectious Diseases1998–2001
  • Rhil 12 For CD4 LESS THAN 50 And Between 300-500National Center For Research Resources2000
  • Lamivudine, Zidovudine, Abacavir, PLUS Amprenavir In HIVNational Center For Research Resources2000
  • HIV RNA Suppression With Ddi/4td/Hu VS Ddi/D4t/EfvNational Center For Research Resources2000
  • Hepatitis C Dynamics With HIV And AIDS TherapyNational Center For Research Resources2000
  • Discontinuing Therapy In Disseminated Mycobacterium AviuNational Center For Research Resources2000
  • Discontinuing PCP Prophylaxis In AIDS Therapy--Cd4>200National Center For Research Resources2000
  • Rhil-12 For HIV-1 Infected Subjects With Cd4<50 And CD4 Between 300-500National Center For Research Resources1998–1999
  • Remune/Triple Antiviral Drugs On HIV-1 Specific Immunogenicity When Cd>400National Center For Research Resources1998–1999
  • Core--DevelopmentalNational Institute Of Allergy And Infectious Diseases1997–1999
  • AIDS ResearchNational Institute Of Allergy And Infectious Diseases1997–1999
  • ACTG 333--Antiviral Effect Of Switching Formulations Of Saquinivir VS IndinvirNational Center For Research Resources1997–1999
  • ACTG 303--Influence Of Risk Status On Response To Antiretroviral InterventionsNational Center For Research Resources1997–1999
  • ACTG 302--Virologic Responses To New Nucleoside Regimens After Prolonged Zdv/DdiNational Center For Research Resources1997–1999
  • ACTG 277--Dapsone Versus Atovaquone For PCP Prophylaxis In HIV Infected PatientsNational Center For Research Resources1997–1999
  • ACTG 244--Zidovudine Alone Or In Combination With Other Antivirals For HIVNational Center For Research Resources1997–1999
  • ACTG 183--Oral Ganciclovir For Cytomegalovirus Gastrointestinal Disease In AIDSNational Center For Research Resources1997–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Flow CytometryNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Comparison Of 3 Recombinant HIV Envelope Vaccines In HIV Infected PatientsNational Center For Research Resources1996–1999
  • Amphotericin B Oral Suspension For Fluconazole Resistant Oral CandidiasisNational Center For Research Resources1997
  • ACTG 223--Clarithromycin In AIDS Patients With Mycobacterium Avium ComplexNational Center For Research Resources1997
  • ACTG 222--Treatment Of Pulmonary Mycobacterium Tuberculosis And HIV InfectionNational Center For Research Resources1997
  • ACTG 214--Comparative Trial Of Several HIV 1 Derived ImmunogensNational Center For Research Resources1997
  • ACTG 177--Prophlaxis Against Mycobacterium Tuberculosis In HIV Positive PatientsNational Center For Research Resources1997
  • Infectious Diseases And Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1996–1997
  • Single Versus Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1996–1997
  • Nucleoside Therapy For Advanced HIV Disease With A CD4 Count <50 MM3National Center For Research Resources1996–1997
  • Differences Among Various Zdv/Ddi Regimens Of Quantitative Measures Of HIVNational Center For Research Resources1996–1997
  • Delavridine Mesylate PLUS ZDV AND/OR DDI VS ZDV PLUS DDI Combination TherapyNational Center For Research Resources1996–1997
  • Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1996–1997
  • Trimethoprim/Sulfamethoxazole As Primary PCP ProphylaxisNational Center For Research Resources1996
  • Influence Of Risk Status On Response To Antiretroviral InterventionsNational Center For Research Resources1996
  • Immunologic And Virologic Responses To Combination Anti-Hiv TherapyNational Center For Research Resources1996
  • Dapsone Versus Atovaquone For PCP Prophylaxis In HIV Infected PatientsNational Center For Research Resources1996
  • Clarithromycin In AIDS Patients With Mycobacterium Avium ComplexNational Center For Research Resources1996
  • Atovaquone PLUS Sulfadiazine Or Pyrimethamine For Toxoplasmic EncephalitisNational Center For Research Resources1996
  • Amphotericin B Oral Suspension For Fluconazole Resistant Oral Candidiasis In HIVNational Center For Research Resources1996
  • Zidovudine Alone Or In Combination With Other Antivirals For HIVNational Center For Research Resources1995–1996
  • Treatment Of Pulmonary Mycobacterium Tuberculosis And HIV InfectionNational Center For Research Resources1995–1996
  • Thalidomide For The Treatment Of Oral And Esophogeal Aphthous Ulcers In HIVNational Center For Research Resources1995–1996
  • Single Versus Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1995–1996
  • Delayed Type Hypersensitivity (DTH) Reactions To HIV Envelope AntigenNational Center For Research Resources1995–1996
  • Alpha Interferon And Nucleoside Analogue Therapy For Hepatitis C In HIVNational Center For Research Resources1995–1996
  • Active Immunization Of Asymptomatic HIV+ Patients With Recombinant GP160National Center For Research Resources1995–1996
  • R0 31-8959 + ZDV VS ZDV + Zalcitabine VS R0 31-8959 + ZDV + ZalcitabineNational Center For Research Resources1994–1996
  • Nucleoside Therapy For Advanced HIV Disease With A CD4 Count <50 MM3National Center For Research Resources1994–1996
  • Comparison Of 3 Recombinant HIV Envelope Vaccines In HIV Infected PatientsNational Center For Research Resources1994–1996
  • Comparative Trial Of Several HIV 1 Derived ImmunogensNational Center For Research Resources1994–1996
  • Prophlaxis Against Mycobacterium Tuberculosis In HIV Positive PatientsNational Center For Research Resources1993–1996
  • Core--Flow CytometryNational Institute Of Allergy And Infectious Diseases1989–1996
  • Study Evaluating Penicillin G And Ceftriaxone Therapies For NeurosyphilisNational Center For Research Resources1995
  • Atovaquone PLUS Sulfadiazine Or Pyrimethamine For Toxoplasmic EcephalitisNational Center For Research Resources1995
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
  • Safety And Efficacy Of Zidovudine For Asymptomatic HIV IndividualsNational Center For Research Resources1993–1995
  • Developmental Immunology ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
  • Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
  • Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1988–1995
  • Single VS Combination Therapy To Prevent Mycobacterium Avium ComplexNational Center For Research Resources1994
  • An Efficacy And Safety Study Of 2'3'Ddi In AIDS Patients With Advanced ARCNational Center For Research Resources1994
  • Active Immunization Of HIV Positive PTS With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1994
  • Infectious Diseases &Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1993–1994
  • Phase I Dose Escalation Study Of Intravenous Hypericin For HIV InfectionNational Center For Research Resources1993–1994
  • Penicillin G /Iv Ceftriaxone Therapy For Neurosyphilis In HIV Positive PatientsNational Center For Research Resources1993–1994
  • Dideoxycytidine For HIV Positive Patients On Prior Zidovudine TherapyNational Center For Research Resources1993–1994
  • Acyclovir Resistant Mucocutaneous Herpes Simplex Disease In AIDSNational Center For Research Resources1993–1994
  • Pathogenicity Of HIV Isolates--Role In Fetal TransmissonNational Institute Of Allergy And Infectious Diseases1992–1994
  • Safety, Efficacy, And Toxicity Of Zidovudine In Early Aids-Related ComplexNational Center For Research Resources1993
  • Phase I-- Efficacy Of 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1993
  • Multiple Drug Treatment Of Mycobacterium Avium In HIV Positive PatientsNational Center For Research Resources1993
  • Efficacy Of Dideoxyinosine For AIDS Or ARC Patients Intolerant To ZidovudineNational Center For Research Resources1993
  • Comparison Of Dideoxyinosine (DDI) And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1993
  • Active Immunization Of HIV Positive Patients With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1993
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
  • Primary Prophylaxis Of Cerebral Toxoplasmosis In HIV Positive PatientsNational Center For Research Resources1992–1993
  • Oral Azithromycin And Pyrimethamine For Toxoplasmic Encephalitis In AIDSNational Center For Research Resources1992–1993
  • Pathogenicity Of HIV Isolates: Role In Fetal TransmissonNational Institute Of Allergy And Infectious Diseases1991–1993
  • DDI And Zvd Therapy For AIDS Or ARC Patients On Long-Term Zvd TreatmentNational Center For Research Resources1991–1993
  • Correlates Or Markers Of Immunity In AIDSNational Institute Of Allergy And Infectious Diseases1987–1993
  • Infectious Diseases And Basic Microbiological MechanismsNational Institute Of Allergy And Infectious Diseases1992
  • Synthetic Hypericin For HIV Infected Patients With LESS THAN 300 CD4 LymphocytesNational Center For Research Resources1992
  • Multiple Drug Regimens For Treatment Of M Avium In HIV Positive PatientsNational Center For Research Resources1992
  • Intradermal GP160 For HIV Patients With MORE THAN 400 CD4 CellsNational Center For Research Resources1992
  • Dideoxycytidine For HIV Positive Patients On Prior Zvd TherapyNational Center For Research Resources1992
  • Correlates Of Markers Of Immunity In AIDSNational Center For Research Resources1992
  • Comparison Of DDI And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1992
  • AZT Treatment For Hiv-Positive Asymptomatic PatientsNational Center For Research Resources1991–1992
  • Active Immunization With Recombinant GP160 HIV-1 AntigenNational Center For Research Resources1991–1992
  • 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1991–1992
  • Fluconazole VS Amphotericin B In Treatment Of Cryptococcal Meningitis In AIDSNational Center For Research Resources1990–1992
  • Efficacy Of DDI For AIDS Or ARC Patients Intolerant To ZDVNational Center For Research Resources1990–1992
  • Bactrim VS Fansidar VS Pentamidine Aerosol For PCP In AIDSNational Center For Research Resources1989–1992
  • AZT Therapy For Patients With Early Aids-Related ComplexNational Center For Research Resources1988–1992
  • Zidovudine And Recombinant Alpha-2a Interferon For Kaposi'S Sarcoma In AIDSNational Center For Research Resources1991
  • Intravenous Spiramycin In AIDS Patients With Cryptosporidial DiarrheaNational Center For Research Resources1991
  • Immediate VS Delayed Foscarnet Therapy For CMV Retinitis In AIDS PatientsNational Center For Research Resources1991
  • Foscarnet Salvage For Immediately Sight-Threatening CMV RetinitisNational Center For Research Resources1991
  • Intravenous Ganciclovir Therapy For Peripheral CMV Retinitis In AIDSNational Center For Research Resources1990–1991
  • Comparison Of 2', 3'(Ddi) And Zidovudine For Patients With AIDS Or ARCNational Center For Research Resources1990–1991
  • Combination Of AZT And DHPG For Patients With AIDS And Cytomegalovirus InfectionNational Center For Research Resources1990–1991
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1989–1991
  • Phase I Trial Of Ribavirin For AIDS And Advanced ARCNational Center For Research Resources1989–1991
  • GM-CSF For Aids-Associated Large Cell Immunoblastin, Sn-Cleaved LymphomaNational Center For Research Resources1990
  • Phase II Study Of 2',3'Dideoxyinosine For Treatment Of Aids/ArcNational Center For Research Resources1989–1990
  • AZT For Hiv-Positive Asymptomatic PatientsNational Center For Research Resources1988–1990
  • Biosynthesis In Normal And Virus Transformed CellsNational Cancer Institute1986–1990
  • Intravenous IL-2 In The Propagation Of Tumor Infiltrating LymphokinesNational Center For Research Resources1989
  • Combination Of AZT And DHPG For Patients With AIDS And CytomegalovirusNational Center For Research Resources1989
  • AIDS Cryptococcal Meningitis--Fluconazile VS Amphotericin B TherapyNational Center For Research Resources1989
  • HTLV-III Infection In Non-Drug Abusing Promiscuous FemalesNational Center For Research Resources1988–1989
  • AZT In Patients With AIDS DementiaNational Center For Research Resources1988–1989
  • AIDS Clinical Trials Unit (Conversion From Ateu)National Institute Of Allergy And Infectious Diseases1988
  • Phase I Trial Of Ribavirin For AIDS And Advanced ARC, Ateu34National Center For Research Resources1988
  • Phase I Of Combination Of AZT And DHPG For Patients With AIDS And CytomegalovirusNational Center For Research Resources1988
  • Intravenous Interleukin-2 In The Propagation Of Tumor Infiltrating LymphokinesNational Center For Research Resources1988
  • Efficacy And Toxicity Of Doxorubicin Treatment In Kaposi SarcomaNational Center For Research Resources1988
  • Bactrim VS Fansidar VS Pentamidine Aerosol For PCP In AIDS, Ateu21National Center For Research Resources1988
  • AIDS Cryptococcal Meningitis--Fluconazile VS Amphotericin B, Ateu26National Center For Research Resources1988
  • Establishment Of AIDS Treatment Evaluation UnitsNational Institute Of Allergy And Infectious Diseases1986–1988
  • HTLV-III Infection In Non-Drug Abusing Promiscuous FemaleNational Center For Research Resources1987
  • Viral And Cellular Gene Expression And Growth RegulationNational Cancer Institute1986–1987
  • Molecular Biology Of Aids-Related TumorsNational Cancer Institute1985–1986
  • Biosynthesis In Normal And Virus-Transformed CellsNational Cancer Institute1985–1986
  • Etiology And Immunological Basis Of The AID SyndromeNational Cancer Institute1985
  • Cellular And Viral Control Of Oncogenic TransformationNational Cancer Institute1985
  • Cell-Mediated Immunity In Humans: Mechanisms And UsesNational Cancer Institute1985

Hospital Affiliations